Profound Medical Secures FDA 510(k) Clearance For TULSA-PRO Thermal Boost
Portfolio Pulse from Benzinga Newsdesk
Profound Medical has secured FDA 510(k) clearance for its TULSA-PRO Thermal Boost, a device that enables surgeons to ablate whole- or partial-gland prostate tissue in patients with varying degrees of prostate cancer.
September 25, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Profound Medical's FDA clearance for TULSA-PRO Thermal Boost could potentially increase the company's market share in the prostate cancer treatment sector.
FDA clearance is a significant milestone for medical device companies. It allows them to market and sell their products in the US. This clearance could potentially increase Profound Medical's market share in the prostate cancer treatment sector, leading to increased revenues and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100